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Abstract
Background: Hemodynamic optimization during surgery is of major importance to decrease postoperative morbidity
and length of hospital stay. However, conventional cardiac output monitoring is rarely used at the bedside. Recently,
the plethysmographic variability index (PVI) was described as a simplified alternative, using plug-and-play noninvasive
technology, but its clinical utility remains to be established.
Methods/design: The hemodynamic optimization using the PVI (OPVI) trial is a multicenter randomized controlled
two-arm trial, randomizing 440 patients at intermediate risk of postoperative complications after orthopedic surgery.
Hemodynamic optimization was conducted using either the PVI (PVI group) or conventional mean arterial pressure
(control group). The anesthesiologist performed the randomization the day before surgery using an interactive web
response system, available 24 hours a day, 7 days a week. The randomization sequence was generated using
permutated blocks and stratified by center and type of surgery (knee or hip arthoplasty). Patients and surgeons,
but not anesthesiology staff, were blinded to the allocation group. The primary outcome measure is the length
of hospital stay following surgery. The attending surgeon, who was blinded to group assessment, determined
hospital discharge. Secondary outcome measures are theoretical length of hospital stay, determined using a
dedicated discharge-from-hospital checklist, postoperative arterial lactate level in the recovery room, postoperative
troponin level, presence of serious postoperative cardiac complications, and postoperative acute kidney insufficiency.
Discussion: The OPVI trial is the first multicenter randomized controlled study to investigate whether perioperative
hemodynamic optimization using PVI during orthopedic surgery could decrease the length of hospital stay and
postoperative morbidity.
Trial registration: ClinicalTrials.gov NCT02207296.
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Background
While more than 200 million surgeries are performed
worldwide each year [1], recent data showed that peri-
operative morbidity and mortality remain significant [2].
Perioperative hemodynamic complications frequently occur
after noncardiac surgery and increase the mortality risk [3].
Perioperative hemodynamic optimization is of major
importance to decrease myocardial injury after non-
cardiac surgery [4], and is recommended in Britain
and France [5, 6]. Initially described using complex
methods, such as oxygen delivery [7], the concept
was simplified to a maximization of stroke volume
using titrated fluid loading with cardiac output moni-
toring [5, 6]. However, although such a strategy is
beneficial for patients, it is rarely used at the bedside
[8]. The invasive cardiac output monitoring method, a
lack of knowledge, and time constraints could partially ex-
plain this disappointing result [8]. The prediction of fluid
loading using cardiopulmonary interaction could be an-
other method of fluid optimization. Initially described
using respiratory arterial pulse pressure variations under
mechanically ventilation [9], a noninvasive alternative has
recently been described using respiratory variations of the
plethysmographic wave form [10].
The plethysmographic variability index (PVI) is deter-
mined using an automated, plug-and-play, totally nonin-
vasive device (Masimo Corporation, Irvine, CA, USA)
that consists of a simple oximetry sensor connected to a
monitor (Radical 7, Masimo Corporation, Irvine, CA),
which responds to the simplified criteria needed at the
bedside. Previous studies reported that PVI could accur-
ately predict fluid responsiveness [11, 12], and that a
forehead sensor could be better than a digital sensor
[13]. However, only a few Phase III studies with heavy
limitations were conducted, to assess the clinical utility
of PVI in decreasing perioperative morbidity [14–16],
and the benefit remains to be established.
The OPVI study aims to compare the effects of PVI
using perioperative hemodynamic algorithm optimization
and a conventional hemodynamic algorithm using mean
arterial pressure in patients with intermediate risk of post-
operative complications after orthopedic surgery.
Methods/design
Ethics and study design
The hemodynamic optimization using the PVI (OPVI)
study is a multicenter randomized controlled two-armtrial.
The institutional review board of the University Hospital of
Caen approved the study for all co-investigator centers
(Registration number ID RDB: 2014-A00330-47, 23 May
2014). The OPVI study is conducted in accordance with
the Declaration of Helsinki, and was registered on 31 July
2014 on the ClinicalTrials.gov website with trial identifica-
tion number NCT02207296. The OPVI trial follows the




Local investigators screen consecutive patients sched-
uled for planned hip or knee arthroplasty in participat-
ing centers. Patients receiving general anesthesia are
eligible for the study.
Patients fulfilling one or more of the following cri-
teria will not be included: lack of informed consent
prior to randomization, cardiac arrhythmia, sepsis, use
Fig. 1 CONSORT diagram for the OPVI trial. PVI, plethysmographic variability index
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of another form of hemodynamic monitoring as cardiac
output monitoring, chronic kidney disease with dialysis,
black skin (owing to limitations in plethysmography
technology), pregnant, younger than 18 years or under
judicial protection. This is to provide good technical
conditions for the PVI and a relatively homogeneous
study population for interpretation of the results.
Included patients were at moderate surgical risk, con-
sidering the surgical procedure or the medical history
for each patient. Patients at high surgical risk, according
to medical history, for whom a cardiac output monitor
could be used [6], will be not included in the study. All
patients are asked for written informed consent, as re-
quired by the institutional review board, in accordance
with the Declaration of Helsinki.
Randomization
Randomization is performed by the anesthesiologist the
day before surgery using an interactive web response
system with Clinsight® software (Ennov, Paris, France),
which is available 24 hours a day, 7 days a week. The
randomization sequence is generated using permutated
blocks and stratified by center and type of surgery (knee
or hip arthoplasty).
Interventions
After hemodynamic stabilization following general
anesthesia induction and orotracheal intubation, included
patients are assigned to either the control group or the
PVI group, according to the randomization.
In the control group (Fig. 2), the hemodynamic goal is
a mean arterial pressure > 65 mmHg; the clinician could
prescribe intravenous fluid challenge using 3 ml/kg of
gelatin for 5 minutes or a vasopressor (ephedrine until
30 mg, and norepinephrine after), or both.
In the PVI group (Fig. 3), the hemodynamic targets are
both the PVI and the mean arterial pressure: the fluid
challenge prescription depends on a PVI value > 13 %, ac-
cording to a previous study [13], while vasopressor use
depends on a mean arterial pressure < 65 mmHg.
Both the control group and the PVI group will undergo
PVI monitoring, which is continuously recorded from
induction of general anesthesia to the end of surgery, but
the monitor is blinded in the control group. All PVI data
will be recovered by an independent investigator not
involved in the patient anesthesia, after surgery. The allo-
cated therapy is delivered until the patient is discharged
from the operating room.
Standard procedures
At arrival in the operating room, each patient undergoes
the usual monitoring, including scope, noninvasive blood
pressure, and pulse oximetry, until discharge from the re-
covery room.
The concomitant use of regional anesthesia, choice of
anesthetic, prophylactic antibiotics, and postoperative pain
management are left to the discretion of the attending
anesthesiologist.
The ventilator patterns indicated by the investigators
are a tidal volume using 8 ml/kg of ideal body weight,
a respiratory frequency and a fraction of inspired oxy-
gen (FiO2) according to a range of end tide carbon di-
oxide (etCO2) between 35 and 45 mmHg, and a
peripheral capillary oxygen saturation (SpO2) > 96 %,
respectively.
Fig. 2 Hemodynamic algorithm for the control group. *Norepinephrine after failure of the use of ephedrine defined by the use of 30 mg
of ephedrine without desired hemodynamic response. Norepinephrine: dosage begins at 0.05 μg/(kg min), and is then adjusted in steps
of 0.05 μg/(kg min). IV, intravenous; IVD, intravenous drip; MAP, mean arterial pressure
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Study endpoint measures
The study endpoint measures are listed in Table 1.
The primary outcome measure is the real length of
hospital stay (in days) following planned hip or knee
arthroplasty under general anesthesia.
The secondary outcome measures are theoretical
length of hospital stay using a dedicated discharge-from-
hospital checklist (see Additional file 1) [18], the postop-
erative arterial lactate level in the recovery room, the
troponin level on postoperative days 1, and 3, whether
there are any serious postoperative cardiac complica-
tions (at least one of the following criteria: cardiac arrest,
arrhythmia, or heart failure requiring a treatment), and
the postoperative acute kidney insufficiency (defined as
an increase of at least 30 % of creatinine compared with
the preoperative level [19]). Abnormal values of lactate
and troponin levels are beyond 2 mmol/l and 0.06 ng/
ml, respectively.
Blinding
A coding list will be generated using the interactive web
response system and each patient from the specific trial
site will be allocated a coding number. During surgery and
postoperative care, both surgeons and patients are blinded
to the allocated group. The material used in the PVI group
and in the control group is similar, in keeping with the
blinded design. Therefore, patients in each group remain
indistinguishable. Only the anesthesiology staff and the
research staff can view the monitor (which is blinded in
the control group) and know the group allocation. The
surgeons are the postoperative care providers, and will de-
cide the length of hospital stay, while remaining totally
blinded to the group allocation. The research staff will use
the objective checklist for hospital discharge twice a day,
at 8 a.m. and 4 p.m. for each included patient.
Intention-to-treat analysis
Patients with severe hypotension following induction of
general anesthesia and requiring norepinephrine, or who
experience serious undesirable events during the surgery,
justifying invasive hemodynamic monitoring (arterial cath-
eter, cardiac output monitoring), will not be treated using
the study group algorithm allocation. They will undergo
different monitoring or treatment at the discretion of the
attending anesthesiologist, but they will be analyzed ac-
cording to their initial assigned group on an intention-to-
treat analysis.
Sample size estimation
Using the French national database, two groups of 193
patients are required to detect a difference of 1 day in the
primary outcome measure between groups, using a
two-sided α-risk at 0.05 and a β-risk at 0.20, assuming
a standard deviation of ±3.5 days for the primary out-
come difference. An interim analysis is planned after
Fig. 3 Hemodynamic algorithm for the PVI group. *Norepinephrine
after failure of the use of ephedrine defined by the use of 30 mg of
ephedrine without desired hemodynamic response. Norepinephrine:
dosage begins at 0.05 μg/(kg min), and is then adjusted in steps of
0.05 μg/(kg min). IV, intravenous; IVD, intravenous drip; MAP, mean
arterial pressure; PVI, plethysmographic variability index
Table 1 Study endpoint measures
Endpoint measure Judgment criteria
Primary endpoint measure Postoperative length of hospital stay Real postoperative length of hospital stay (days)
Secondary endpoint measures Theoretical postoperative length of
hospital stay
Theoretical postoperative length of hospital stay using a checklist (days)
Postoperative arterial lactate level in
recovery room
Proportion of patients with lactate levels > 2 mmol/l
Postoperative troponin level at days
1 and 3
Proportion of patients with troponin Ic > 0.06 ng/ml
Serious postoperative cardiac
complications
Proportion of patients with at least one of: cardiac arrest, arrhythmia, and
heart failure requiring treatment
Postoperative kidney insufficiency Proportion of patients with an increase of at least 30 % in creatinine level
compared with preoperative value
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enrollment of the first 200 patients, to check the length
of hospital stay after surgery in each group and perform
a futility assessment with conditional power. We antici-
pate no missing data for the primary outcome measure
(length of hospital stay following surgery). However, we
plan to conduct multiple imputation in the case of missing
data. For per-protocol analysis (sensitivity analysis), the
need to handle missing data (failure of PVI monitoring;
hypotension following induction of general anesthesia
leading to a requirement for norepinephrine; or serious
undesirable events during the surgery) will be anticipated
by including 27 additional patients for each group. Never-
theless, all randomized patients will be analyzed in the
allocated group for the main, intention-to-treat, analysis.
In addition, to comply with the intention-to-treat analysis,
missing data for the primary outcome will handled by
multiple imputation (PROC MI in SAS) and analyzed in
sensitivity analyses using PROC MIANALYSE in SAS
version 9.4 (SAS institute, Cary, NC, USA).
Statistical plan
Categorical variables will be described as percentages;
continuous variables will be described as mean (with
standard deviation) or median (interquartile range), as
appropriate. The analysis for the primary outcome
will follow the intention-to-treat principle, in which
all the randomized patients will be analyzed in the
assigned group. The principal comparison will be per-
formed by a multivariate linear regression of the LOS,
including the group and stratification factors (center
and type of surgery) as independent variables. The
normal distribution of the primary outcome will be
tested by the Kolmogorov–Smirnov test. Logarithmic
transformation will be conducted before analysis in
the case of significant departure from the normal dis-
tribution. Categorical variables will be compared between
groups using the Fisher exact test or the Pearson chi-
square test for heterogeneity. All statistical analysis will be
conducted using SAS version 9.4 (SAS institute, Cary, NC,
USA). Statistical significance will be assumed for P < 0.05.
Registration
Data will be collected and registered using electronic case
report forms in each center by a dedicated local technical
research team. A research coordinator will centralize data
from all sites.
Data collected and registered
Baseline characteristics and prerandomization data will be
recorded: sex, age, height, weight, ideal body weight, Lee
score [20], smoking status, history and type of diabetes mel-
litus, dyslipidemia, history of cardiovascular disease (sys-
temic hypertension, ischemic heart disease, valvular heart
disease, peripheral vascular disease, cardiac medications),
history of respiratory disease (asthma, chronic obstructive
pulmonary disease) using the PROVILHO study criteria
[21], history of hepatic disease (Child Pugh classification of
cirrhosis [22]), renal insufficiency (classified according to
the glomerular filtration rate [23]), history of neoplasia (ac-
tive or remission), and blood sample (creatinine, bilirubin,
albumin, rate of prothrombin).
During the anesthesia and surgical procedures, the fol-
lowing will be recorded: type of procedure (first or reopera-
tion), surgical site (hip or knee arthroplasty), duration of
anesthesia and surgery, blood loss and transfusion require-
ments, all drugs used during anesthesia (anesthetics, opi-
ates, neuromuscular blocking agent), all administered fluids
(number of titrated fluid loading and total fluid loading),
and all vasoactive drugs.
After the procedure and before the extubation, the blood
lactate level will be recorded. Data from the Radical-7
monitor will be extracted (mean PVI, percentage of time
that PVI < 13 %, mean heart rate). The mean arterial pres-
sure, the ratio of mean arterial pressure to heart rate, and
the percentage of time that the mean arterial pressure is
less than 65 mmHg and less than 55 mmHg, will be ex-
tracted from the conventional monitor.
During postoperative days 1, 3, and 5, blood sam-
ples will be taken, to assess creatinine, troponin, and
hemoglobin levels.
From postoperative day 0 until discharge from hospital,
any postoperative complications will be recorded (Table 1).
The real and theoretical (using the checklist) hospital
length of stay and the survival status at day 30 following
inclusion will be recorded.
Record keeping
Consent forms and electronic case report forms will be
stored for 15 years in each center, in accordance with
French law.
Study organization
The study promotion is performed by the University
Hospital of Caen, France. There is neither industrial fi-
nancial support nor industrial involvement in the study
protocol.
Duration and timeline
Patients from five French university hospitals (Caen,
Amiens, Lille, Rouen) will be included during a two-year
inclusion period, beginning in February 2015.
The protocol, approval from the ethical committee,
financial support, electronic case report forms, and
interactive web response system were developed in
2014. Inclusion of patients is planned for 2015 and
2016. The database will be closed in 2017, after which
data analysis, manuscript writing, and submission for
publication will follow.
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Discussion
Perioperative hemodynamic complications frequently
occur after noncardiac surgery and increase the risk
of mortality [3]. Although perioperative hemodynamic
optimization is of major importance to decrease myo-
cardial injury [4], it has rarely been applied [8]. The
OPVI trial is the first randomized controlled multi-
center study powered to investigate the PVI as a
noninvasive hemodynamic tool in patients scheduled
for orthopedic surgery.
The primary endpoint measure of the trial is the real
length of hospital stay after planned hip or knee arthro-
plasty. This endpoint measure depends on the periopera-
tive morbidity, and will reveal the clinical impact of a
hemodynamic algorithm using PVI. The definition of the
main outcome measure is challenging [24], but it seems
more appropriate and relevant in evaluating the clinical
utility of PVI at the bedside. Moreover, the sample size
could be calculated using a minimal hospital length of stay,
in practice equal to 3 days, rather than 0 days, which could
introduce statistical bias. For example, the sample size cal-
culation for a difference of 1 day between the control
group (5 days) and the PVI group (4 days) could corres-
pond to a decrease in hospital length of stay equal to 20 %,
if calculated from the first day, or of 50 %, if calculated
from the third day, which corresponds to the minimal
length of stay observed in practice. However, the standard
deviations are larger in this simulation and could decrease
the interest of this calculation. As a secondary objective,
we evaluate the theoretical hospital length of stay using an
objective evaluation with a specified checklist used by ded-
icated research staff (see Additional file 1) twice a day, at
8 a.m. and 4 p.m. for each included patient. The other
secondary endpoint measures determine: (1) oxygen debt,
using the blood lactate level in the recovery room, which
represents an immediate postoperative prognostic value
[25]; and (2) postoperative troponin level [3], cardiac com-
plications [26], or kidney insufficiency [27], which have
both short- and long-term prognostic value.
Patients requiring high-risk surgery were not se-
lected for inclusion in study population, because PVI
hemodynamic monitoring is considered for intermedi-
ate surgical risk [6]. This population of patients is the
more frequently observed in practice [2]. Inclusion
criteria were large for the study population, reinfor-
cing the external validity of the study.
Some comments could be addressed concerning the
limitations of the study. First, the study population was
restricted to patients requiring orthopedic surgery with
intermediate surgical risk. Further studies could be devel-
oped with other types of surgery that have intermediate
surgical risk. Second, the medico-economic of PVI use is
not evaluated in the present study, but an ancillary study
is proposed, to follow it.
In conclusion, the OPVI trial is a multicenter controlled
randomized trial, powered to test the hypothesis that peri-
operative hemodynamic optimization using the PVI algo-
rithm could decrease the length of hospital stay after
orthopedic surgery in patients with intermediate surgical
risk. The OPVI trial also evaluates the impact of the PVI
algorithm on postoperative cardiac complications (at least
one of the following criteria: cardiac arrest, arrhythmia,
and heart failure requiring treatment), postoperative
troponin level, incidence of postoperative kidney insuffi-
ciency, and postoperative blood lactate level.
Trial status
The trial is ongoing and is actively enrolling patients.
Additional file
Additional file 1: Discharge-from-hospital checklist. All items must
be checked ‘yes’ for the patient to be considered for discharge at the
time of checklist completion (8 a.m. or 4 p.m.); this time serves to
quantify the theoretical length of hospital stay. (DOCX 67 kb)
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